

LAVORI IN EXTENSO PUBBLICATI SU RIVISTE CON IMPACT FACTOR (al 2012)

- AA 1. CHIARAMONTE M., **FLOREANI A.**, GIANI G., PORNARO E., NACCARATO R. Sex differences in HBsAg and antiHBs distribution. *Hepato-Gastroenterology* 29: 13-14, 1982. **IF 0.774**
- AA 2. CHIARAMONTE M., **FLOREANI A.**, VENTURI PASINI C., RUFFATTI A., OKOLICSANYI L., NACCARATO R. Primary biliary cirrhosis in sisters: a case report. *Ital. J.Gastroenterol.(now Dig Liver Dis)* 14: 169-171, 1982. **IF 3.162**
- AA 3. CHIARAMONTE M., **A. FLOREANI**, NACCARATO R. Hepatitis B Virus Infection in Homes for the Aged. *J.Med.Virol.* 9: 247-255, 1982. **IF 2.373**
- AA 4. CHIARAMONTE M., **FLOREANI A.**, MARTINES D., DE LAZZARI F., NACCARATO R. Hepatitis B Virus Infection and Cyclophosphamide. *Ann.Int.Med.* 97, 3: 451-452, 1982 (letter). **IF 13.976**
- AA 5. **FLOREANI A.**, CHIARAMONTE M., NACCARATO R. Acute Hepatitis in Elderly Patients. *Arch. Intern. Med. (now JAMA International Medicine)* 143: 1829, 1983 (letter). **IF 29.978**
- AA 6. MEANI A., PICCOLI A., CHIARAMONTE M., **FLOREANI A.**, DEL FAVERO G., FARINI R., NACCARATO R. Third complement component in acute hepatic failure: a prognostic aid. *Ital. J. Gastroenterol.(now Dig Liver Dis)* 15: 274: 277, 1983 (letter). **IF 3.162**
- AA 7. CHIARAMONTE M., **FLOREANI A.**, SILVAN C., ZAMPIERI L., TRIVELLO R., RENZULLI G., MOSCHEN M.E., NACCARATO R. Hepatitis A and Hepatitis B Virus Infection in Children and Adolescents in North-East Italy. *J.Med.Virol.* 12: 179-186, 1983. **IF 2.373**
- AA 8. RUFFATTI A., ARSLAN P., **FLOREANI A.**, DE SILVESTRO G., CALLIGARO A., NACCARATO R., TODESCO S. Nuclear Membrane-Staining Antinuclear Antibody in: Patients with Primary Biliary Cirrhosis. *J. Clin. Immunol.* 5: 357-361, 1985. **IF 3.382**
- AA 9. CHIARAMONTE M., **FLOREANI A.**, NACCARATO R. Hepatitis B virus (HBV) in the elderly: an underestimated problem? *Biomedicine & Pharmacotherapy* 41: 121-123, 1987. **IF 2.068**
- AA 10. **FLOREANI A.**, BIRD P., MITCHISON H., JAMES O., BASSENDINE M. Abnormal subclass distribution of immunoglobulin in primary biliary cirrhosis. *Ital. J.Gastroenterol.* 19: 325-328, 1987. **IF 3.162**
- AA 11. BALDO-ENZI G., BAIOCCHI M.R., GROTTO M., **FLOREANI A.**, ZAGOLIN M., CHIARAMONTE M., CERA F., FELLIN R. Lipoprotein Pattern and Plasma Lipoprotein Lipase Activities in Patients with Primary Biliary Cirrhosis. Relationship with Increase of HDL 2 Fraction in Lp-X-Positive and Lp-X-Negative Subjects. *Dig. Dis. Sci.* 33: 1201-1207, 1988. **IF 2.260**
- AA 12. **FLOREANI A.**, BASSENDINE M.F., MITCHISON H., FREEMAN R., JAMES O.F.W. No specific association between primary biliary cirrhosis and bacteriuria? *J. Hepatol.* 8: 201-207, 1989. **IF 9.858**
- AA 13. **FLOREANI A.**, BENNETT M.K., MITCHISON H.C., McLACHLAN S.M., BASSENDINE M.F., JAMES O.F.W. Progression of autoimmune damage in primary biliary cirrhosis: an immunohistochemical study. *Autoimmunity* 2: 311-321, 1989. **IF 2.767**
- AA 14. PLEBANI M., CHIARAMONTE M., **FLOREANI A.**, BERTORELLE R., NACCARATO R., BURLINA A. Two new serum immunoassays (RIA and EIA) for the determination of M2 antimitochondrial antibodies in primary biliary cirrhosis. *Clin.Chim.Acta* 181: 201-206, 1989. **IF 2.850**
- AA 15. PATERNOSTER D.M., **FLOREANI A.**, BURRA P. Liver transplantation and pregnancy (letter). *Int J Gynecol Obst* 50: 199-200, 1995. **IF 1.836**
- AA 16. **FLOREANI A.**, CHIARAMONTE M., GIANNINI S., MALVASI L., LODETTI M.G., CASTRIGNANO R., GIACOMINI A., D'ANGELO A., NACCARATO R. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. *J. Hepatol.* 12: 217-223, 1991. **IF 9.858**

- AA 17. MARTIN A., CASTAGLIUOLO I., **FLOREANI A.**, DE LAZZARI F., STURNIOLO G.C., DI MARIO F., DEL FAVERO G., MASTROPAOLO G., NACCARATO R. Eosinophilic gastroenteritis: Report of two atypical cases. *Ital.J.Gastroenterol.* 23: 81-85, 1991. **IF 3.162**
- AA 18. **FLOREANI A.**, CHIARAMONTE M., FABRIS P., NGATCHU T., NACCARATO R. Poor effect of ursodeoxycholic acid in anti-hepatitis C virus-positive chronic liver disease. *Curr.Ther.Res.* 50: 579-585, 1991. **IF 0.446**
- AA 19. DE PALO E., GATTI R., VARNIER M., **FLOREANI A.**, DE PALO C., SCANDELLARI C. Plasma Acetyl-Carnitine Concentrations during and after Muscular Exercise Test in Patients with Liver Disease. *Eur.J.Clin.Chem.Clin.Biochem (now Eur J Clin Investigation)* 30: 179-186, 1992. **IF 3.365**
- AA 20. **FLOREANI A.**, BERTIN T., SOFFIATI G., NACCARATO R., CHIARAMONTE M. Anti-Hepatitis C Virus in the Elderly: A Seroepidemiological Study in a Home for the Aged. *Gerontology* 38: 214-216, 1992. **IF 2.676**
- AA 21. FABRIS P., BETTERLE C., **FLOREANI A.**, GREGGIO N.A., DE LAZZARI F., NACCARATO R., CHIARAMONTE M. Development of type I diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. *Lancet* 340: 548, 1992 (letter). **IF 39.060**
- AA 22. **FLOREANI A.**, BERTIN T., SOFFIATI G., NACCARATO R., CHIARAMONTE M. Are homes for the elderly still a risk area for HBV infection? *Eur. J.Epidemiol.* 6: 808-811, 1992. **IF 5.118**
- AA 23. **FLOREANI A.**, CHIARAMONTE M., VENTURINI R., PLEBANI M., MARTIN A., GIACOMINI A., NACCARATO R. Antigliadin antibody classes in chronic liver disease. *Ital.J.Gastroenterol.(now Dig Liver Dis)* 24: 457-460, 1992. **IF 3.162**
- AA 24. **FLOREANI A.**, CORSI N., MARTINES D., VARNIER M., NACCARATO R. No effect of endurance exercise on serum bilirubin in healthy athletes and with congenital hyperbilirubinemia. *J. Sports. Med. Phys. Fitness.* 33: 79-82, 1993. **IF 0.730**
- AA 25. **FLOREANI A.**, BIAGINI M.R., CHIARAMONTE M., MILANI S., SURRENTI C., NACCARATO R. Incidence of hepatic and extra-hepatic malignancies in primary biliary cirrhosis (PBC). *Ital J. Gastroenterol. (now Dig Liver Dis)* 25: 473-476, 1993. **IF 3.162**
- AA 26. **FLOREANI A.**, ZAPPALA' F., MAZZETTO M., NACCARATO R., PLEBANI M., CHIARAMONTE M. Different Response to Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis According to Severity of Disease. *Digest. Dis. Sci.* 39: 9-14, 1994. **IF 2.260**
- AA 27. **FLOREANI A.**, PATERNOSTER D., GRELLA V., SACCO S., GANGEMI M., CHIARAMONTE M. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy. *BJOG* 101: 64-65, 1994. **IF 3.760**
- AA 28. DE LAZZARI F., FABRIS P., **FLOREANI A.**, BORTOLAMI M., VENTURI C., CHIARAMONTE M., NACCARATO R. Tumour necrosis factor alpha behaviour in serum during recombinant-alpha-2b-interferon treatment of chronic viral hepatitis. *Eur. J. Gastroenterol. & Hepatol.* 6: 625-628, 1994. **IF 1.915**
- AA 29. **FLOREANI A.**, CHIARAMONTE M. Hepatitis in Nursing Homes. Incidence and Management Strategies. *Drugs & Aging* 5: 96-101, 1994. **IF 2.646**
- AA 30. **FLOREANI A.**, INFANTOLINO D., DE LAZZARI F., BIASIN M.R., VENTURI C., ZAPPALA' F., CHIARAMONTE M., NACCARATO R. Hepatocellular proliferation, TNF alpha and inflammation in primary biliary cirrhosis (PBC). Former *Int. Hepatol.Comm.(now Hepatol Res)* 2: 230-234, 1994. **IF 2.072**
- AA 31. FARINATI F., **FLOREANI A.**, DE MARIA N., FAGIUOLI S., NACCARATO R., CHIARAMONTE M. Hepatocellular carcinoma in primary biliary cirrhosis. *J. Hepatol.* 21: 315-316, 1994. **IF 9.858**
- AA 32. **FLOREANI A.**, MARCHIORI M., BONATO S., ZUCCHETTO M., NACCARATO R., CHIARAMONTE M. Cognitive Assessment in Primary Biliary Cirrhosis: A Case-Control Study. *Am. J. Gastroenterol.* 90: 250-253, 1995. **IF 7.553**

- AA 33. FARINATI F., CARDIN R., DE MARIA N., DELLA LIBERA G., MARAFIN C., LECIS E., BURRA P., **FLOREANI A.**, CECCHETTO A., NACCARATO R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. *J. Hepatol.* 22: 449-456, 1995. **IF 9.858**
- AA 34. DE LAZZARI F., DE SILVESTRO G., **FLOREANI A.**, FABRIS P., CHIARAMONTE M., ONGARO G., NACCARATO R. Recombinant-alpha 2b-Interferon treatment in patients with chronic active hepatitis: effects on peripheral blood mononuclear cells and correlation with response. *Curr. Ther. Res.* 56: 419-428, 1995. **IF 0.446**
- AA 35. CHIARAMONTE M., STROFFOLINI T., LORENZONI U., MINNITI F., CONTI S., **FLOREANI A.**, NTAKIRUTIMANA E., VIAN A., NGATCHU T., NACCARATO R. Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. *J. Hepatol.* 24: 129-134, 1996. **IF 9.858**
- AA 36. **FLOREANI A.**, PATERNOSTER D., ZAPPALA' F., CUSINATO R., BOMBI G., GRELLA P., CHIARAMONTE M. Hepatitis C virus infection in pregnancy. *BJOG* 103: 325-329, 1996. **IF 3.760**
- AA 37. **FLOREANI A.**, PATERNOSTER D.M., MELIS A., GRELLA P.V. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. *Eur. J. Obstet. Gynecol. Repr. Biol.* 67: 109-119, 1996. **IF 1.843**
- AA 38. FARINATI F., CARDIN R., NACCARATO R., **FLOREANI A.** Cysteine and glutathione in the liver of patients with primary biliary cirrhosis. (letter). *J. Hepatol.* 25 : 123, 1996. **IF 9.858**
- AA 39. **FLOREANI A.**, NACCARATO R., CHIARAMONTE M. Prevalence of familial disease in primary biliary cirrhosis in Italy. *J. Hepatol.* 26 : 737-738, 1997. **IF 9.858**
- AA 40. **FLOREANI A.**, BIAGINI M.R., ZAPPALA F., FARINATI F., PLEBANI M., RUGGE M., SURRENTI C., NACCARATO R. Chronic atrophic gastritis and helicobacter pylori infection in primary biliary cirrhosis a cross-sectional study with matching. *Ital. J. Gastroenterol. Hepatol. (now Dig Liver Dis)* 29 : 13-17, 1997. **IF 3.162**
- AA 41. **FLOREANI A.**, ZAPPALA' F., FRIES W., NACCARATO R., PLEBANI M., D'ANGELO A., CHIARAMONTE M. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. *J. Clin. Gastroenterol.* 24 : 239-244, 1997. **IF 3.203**
- AA 42. MOSCHEN M.E., **FLOREANI A.**, ZAMPARO E., BALDO V., MAJORI S., GASPARINI V., TRIVELLO R. Hepatitis A infection : a seroepidemiological study in young adults in North-East Italy. *Eur. J. Epidemiol.* 13 : 875-878, 1997. **IF 5.118**
- AA 43. LOBELLO S., LORENZONI U., VIAN A., **FLOREANI A.**, BRUNETTO M.R., CHIARAMONTE M. Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B : a role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring. *J. Vir. Hepat.* 5 : 61-66, 1998. **IF 3.082**
- AA 44. **FLOREANI A.**, CHIARAMONTE M, GREGGIO N.A., FABRIS P., DE LAZZARI F., NACCARATO R., BETTERLE C. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients. *Ital.J.Gastroenterol.Hepatol.(now Dig Liver Dis)* 30: 71-76, 1998. **IF 3.162**
- AA 45. FARINATI F., DE BONA M., **FLOREANI A.**, FOSCHIA F., RUGGE M. Helicobacter pylori and the liver: any relationship? *Ital.J.Gastroenterol.Hepatol.(now Digest Liver Dis)* 30: 124-128, 1998. **IF 3.162**
- AA 46. **FLOREANI A.**, LOBELLO S., BRUNETTO M., ANELONI V., CHIARAMONTE M. Colchicine in chronic hepatitis B: a pilot study. *Aliment. Pharmacol. Ther.* 12: 653-656, 1998. **IF 4.548**
- AA 47. **FLOREANI A.**, TIZIAN L., LUISETTO G., BUDA A., MEGA A., NACCARATO R. Effects of alendronate sodium on severe osteodystrophy in postmenopausal patients with primary biliary cirrhosis: a pilot study. *Curr. Ther. Res.* 59: 589-593, 1998. **IF 0.446**

- AA 48. **FLOREANI A.**, FRIES W., LUISETTO G., BURRA P., FAGIUOLI S., BOCCAGNI P., ROSELLI DELLA ROVERE G., PLEBANI M., PICCOLI A., NACCARATO R. Bone metabolism in orthotopic liver transplantation: a prospective study. *Liver Transpl* 4: 311-319, 1998. **IF 3.944**
- AA 49. **FLOREANI A.**, INFANTOLINO D., BIASIN R., ROSELLI DELLA ROVERE G., BIAGINI M.R., MELIS A., CHIARAMONTE M. Tumour necrosis factor alpha and cellular proliferation in primary biliary cirrhosis. *Ital J Gastroenterol Hepatol (now Dig Liver Dis)* 31: 56-60, 1999. **IF 3.162**
- AA 50. **FLOREANI A.**, ZANCAN L., MELIS A., BARAGIOTTA A., CHIARAMONTE M. Primary sclerosing cholangitis (PSC): clinical, laboratory and survival analysis in children and adults. *Liver* 19: 228-233, 1999. (now *Liver Int*) **IF 3.870**
- AA 51. CHIARAMONTE M., STROFFOLINI T., VIAN A., STAZI M.A., **FLOREANI A.**, LORENZONI U., LOBELLO S., FARINATI F., NACCARATO R. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. *Cancer* 85: 2132-2137, 1999. **IF 5.201**
- AA 52. **FLOREANI A.**, BARAGIOTTA A., BALDO V., MENEGON T., FARINATI F., NACCARATO R. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. *Hepatology* 29: 1425-1428, 1999. **IF 12.003**
- AA 53. D'ODORICO A., MELIS A., BARAGIOTTA A., MARTINES D., NACCARATO R., **FLOREANI A.** Oxygen-derived free radical production by peripheral blood neutrophils in chronic cholestatic liver diseases. *Hepato-gastroenterology* 46; 1831-1835, 1999. **IF 0.774**
- AA 54. **FLOREANI A.**, MOLARO M., BARAGIOTTA A., NACCARATO R. Chronic cholestasis associated with Turner's syndrome. *Digestion* 60: 587-589, 1999. **IF 1.940**
- AA 55. **FLOREANI A.**, BARAGIOTTA A., MARTINES D., NACCARATO R., D'ODORICO A. Plasma antioxidant levels in chronic cholestatic liver diseases. *Aliment Pharmacol Ther* 14: 353-358, 2000. **IF 4.548**
- AA 56. BALDO V., **FLOREANI A.**, MENEGON T., GRELLA P., PATERNOSTER DM., TRIVELLO R. Hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection in pregnant women in North-East Italy: a seroepidemiological study. *Eur J Epidemiol* 16: 87-91, 2000. **IF 5.118**
- AA 57. **FLOREANI A.**, MIONI D., CHIARAMONTE M., NACCARATO R. Double-blind controlled study of tauroursodeoxycholic acid in elderly patients with hepatitis C virus-related cirrhosis. *Curr Ther Res* 60: 550-557, 1999 **IF 0.446**
- AA 58. FABRIS P., BIASIN MR., INFANTOLINO D., TOSITTI G., VENZA E., **FLOREANI A.**, ZANETTI A., de LALLA F. TTV infection in patients with acute hepatitis of defined aetiology and in a non-A-E hepatitis. *J Hepatol* 32: 661-665, 2000. **IF 9.858**
- AA 59. BALDO V., **FLOREANI A.**, MENEGON T., ANGIOLELLI G., TRIVELLO R. Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. *Gerontology* 46: 194-198, 2000. **IF 2.676**
- AA 60. **FLOREANI A.**, BALDO V., BUORO S, MAZZARIOL L., FAVARATO G., TRIVELLO R. Prevalence of infection with an unenveloped DNA virus (TTV) in elderly subjects. *J Am Geriatr Soc*, 48: 1534-1536, 2000 **IF 3.978**
- AA 61. **FLOREANI A.**, MOLARO M., MOTTES M., SANGALLI A., BARAGIOTTA A., RODA A., NACCARATO R., CLEMENTI M. Benign recurrent intrahepatic cholestasis (BRIC) unlinked to 18q21 and 2q24: a new autosomal dominant entity. *Am J Med Genet*, 95: 450-453, 2000 **IF 2.304**
- AA 62. ALMASIO P., **FLOREANI A.**, CHIARAMONTE M., PROVENZANO G., BATTEZZATI P.M., PODDA M., TODROS L., ROSINA F., SACCOCCIO G., MANENTI F., BALLARDINI G., BIANCHI F.P., SCHEUER P.J., DAVIES S.E., CRAXI' A. The Italian multicentre randomized controlled trial of ursodeoxycholic acid plus colchicine in symptomatic primary biliary cirrhosis. *Aliment Pharmacol Ther*. 14: 1645-1652, 2000 **IF 4.548**
- AA 63. **FLOREANI A.**, BALDO V., CHIARAMONTE M. (letter) Reply to Epidemiology of hepatitis C virus

infection in the elderly. *Gerontology* 47: 117-118, 2001. **IF 2.676**

- AA 64. BALDO V., MENEGON T., BONELLO C., **FLOREANI A.**, TRIVELLO R., Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. *Vaccine* 19: 3472-3475, 2001. **IF 3.492**
- AA 65. PATERNOSTER D.M., SANTAROSSA C., GRELLA P., PALU' G., BALDO V., BOCCAGNI P., **FLOREANI A.** Viral load in HCV-RNA-positive pregnant women. *Am J Gastroenterol* 96: 2751-2754, 2001. **IF 7.553**
- AA 66. **FLOREANI A.**, MEGA A., TIZIAN L., BURRA P., BOCCAGNI P., BALDO V., FAGIUOLI S., NACCARATO R., LUISETTO G. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. *Osteoporos Int* 12: 749-754, 2001. **IF 4.039**
- AA 67. **FLOREANI A.**, GUIDO M., BORTOLAMI M., DELLA ZENTIL G., VENTURI C., PENNELLI N., NACCARATO R. Relationship between apoptosis, tumour necrosis factor, and cell proliferation in chronic cholestasis. *Dig Liver Dis* 33: 570-575, 2001. **IF 3.162**
- AA 68. **FLOREANI A.**, COLLOREDO G., LOBELLO S., DI MARCO M., POPOVIC A., NACCARATO R. Preliminary results of a two-center trial with colchicine for the treatment of chronic hepatitis B. *Am J Gastroenterol (letter)* 96: 3451-3452, 2001. **IF 7.553**
- AA 69. AGARWAL K., JONES D.E.J., WATT F.E., BURT A.D., **FLOREANI A.**, BASSENDINE M.F. Familial primary biliary cirrhosis and autoimmune cholangitis *Digt Liver Dis* 34: 50-52, 2002. **IF 3.162**
- AA 70. **FLOREANI A.**, BARAGIOTTA A., PIZZUTI D., MARTINES D., CECCHETTO A., CHIARELLI S. Mucosal IgA defect in primary biliary cirrhosis. *Am J Gastroenterol* 96: 508-510, 2002. **IF 7.553**
- AA 71. PATERNOSTER D.M., FABRIS F., PALU' G., SANTAROSSA C., BRACCIANTE R., SNIJDERS D., **FLOREANI A.** Intra-hepatic cholestasis of pregnancy in hepatitis C virus infection. *Acta Obstet Gynecol Scand* 81: 99-103, 2002. **IF 1.850**
- AA 72. DE LAZZARI F., RAVAGNAN P., TENDERINI M., VICARIOTO M.A., GALLIANI E.A., LORENZONI U., POPOVIC A., **FLOREANI A.** Circulating soluble-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease. *Hepatogastroenterology* 49: 231-234, 2002. **IF 0.774**
- AA 73. **FLOREANI A.**, BETTERLE C., BARAGIOTTA A., MARTINI S., VENTURI C., BASSO D., PITTONI M., CHIARELLI S., SATEGNA GUIDETTI C. Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. *Dig Liver Dis* 33: 258-261, 2002. **IF 3.162**
- AA 74. **FLOREANI A.**, PATERNOSTER D., MEGA A., FARINATI F., PLEBANI M., BALDO V., GRELLA P. Sex hormone profile and endometrial cancer risk in primary biliary cirrhosis: a case-control study. *Eur J Obst Gynecol Repr Biol* 103: 154-157, 2002. **IF 1.843**
- AA 75. **FLOREANI A.** Osteoporosis is not a specific complication of primary biliary cirrhosis (PBC). *Gut* 50: 898-899, 2002 (letter) **IF 10.732**
- AA 76. BALDO V., **FLOREANI A.**, DAL VECCHIO L., CRISTOFOLETTI M., CARLETTI M., MAJORI S., DI TOMMASO A., TRIVELLO R. Occupational risk of blood-borne viruses in healthcare workers: a 5-year surveillance program. *Infect Control Hosp Epidemiol* 23: 325-327, 2002. **IF 4.020**
- AA 77. BORTOLAMI M., VENTURI C., GIACOMELLI L., SCALERTA R., BACCHETTI S., MARINO F., **FLOREANI A.**, LISE M., NACCARATO R. Cytokine, infiltrating macrophage and T-cell mediated response to development of primary and secondary human liver cancer. *Dig Liver Dis* 34: 794-780, 2002. **IF 3.162**
- AA 78. **FLOREANI A.**, BARAGIOTTA A., GUIDO M. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: a cause of resistance to ursodeoxycholic treatment. *Dig Liver Dis* 35: 128-129, 2003 **IF 3.162**

- AA 79. OKOLICSANYI L., GROPPA M., **FLOREANI A.**, MORELLI-LABATE A.M., RUSTICALI A.G., BATTOCCHIA A., COLOMBO M., GALATOLA G., GASBARRINI G., PODDA M., RICCI G., ROSINA F., ZUIN M. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of retrospective Italian multicentre survey. *Dig Liver Dis* 35: 325-331, 2003. **IF 3.162**
- AA 80. DI LEO V., VENTURI C., BARAGIOTTA A., MARTINES D., **FLOREANI A.** Gastroduodenal and intestinal permeability in primary biliary cirrhosis. *Eur J Gastroenterol Hepatol* 15: 967-973, 2003. **IF 1.915**
- AA 81. NERI T.M., , CAVESTRO G.M., SEGHINI P., ZANELLI P.F., ZANETTI A., SAVI M., PODDA M., ZUIN M., COLOMBO M., **FLOREANI A.**, ROSINA F., BIANCHI PORRO G., STRAZZABOSCO M., OKOLICSANYI L. Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a Southern European population. *Dig Liver Dis* 35: 571:576, 2003.. **IF 3.162**
- AA 82. **FLOREANI A.**, BARAGIOTTA A., LEONE M.G., BALDO V., NACCARATO R. Primary biliary Cirrhosis and hepatitis C virus infection. *Am J Gastroenterol* 98: 2757-2762, 2003 . **IF 7.553**
- AA 83. FABRIS P., **FLOREANI A.**, TOSITTI G., VERGANI D., de LALLA F., BETTERLE C. Type-1 Diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. *Aliment Pharmacol Ther* 18: 549-558, 2003. **IF 4.548**
- AA 84. BALDO V., MARCOLONGO A., **FLOREANI A.**, MAJORI S., CRISTOFOLETTI M., DAL ZOTTO A., VAZZOLER G., TRIVELLO R. Epidemiological aspect of traumatic brain injury in northeast Italy. *Eur J Epidemiol* 18: 1059-1063, 2003. **IF 5.118**
- AA 85. **FLOREANI A.**, BALDO V., CRISTOFOLETTI M., RENZULLI G., VALERI A., ZANETTI C., TRIVELLO R. Long-term persistence of anti-HBs after vaccination against HBV: a 18 year experience in Health Care Workers. *Vaccine* 22: 607-610, 2003. **IF 3.492**
- AA 86. MACCHI V., **FLOREANI A.**, MARCHESI P., PASINI R., ZULIANI M., FELTRIN G.P., De CARO R., MIOTTO D. Imaging of primary sclerosing cholangitis: preliminary results by two new non-invasive techniques. *Dig Liver Dis* 36: 614-621, 2004. **IF 3.162**
- AA 87. BERGASA N.V., MASON A., **FLOREANI A.**, HEATHCOTE J., SWAIN M.G., JONES D.E., LINDOR K.M., BASSENDINE M.F., WORMAN H.J. Primary biliary cirrhosis: report of a focus study group. *Hepatology* 40: 1013-1020, 2004. **IF 12.003**
- AA 88. FABRIS P., **FLOREANI A.**, CARLOTTO A., GIORDANI M.T., BALDO V., STECCA C., MARCHIORO L., TRAMARIN A., BERTIN T., NEGRO F., de LALLA F. Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C. *J Hepatol* 41: 644-651, 2004. **IF 9.858**
- AA 89. BARAGIOTTA A., **FLOREANI A.**, AGARWAL K, VENTURI C., CRAGGS A., JONES D., DONALDSON P.T., BASSENDINE M.F. Chemokine receptor 5 and primary biliary cirrhosis: a two-centre genetic association study. *Liver Int* 24: 646-650, 2004 **IF 3.870**
- AA 90. FABRIS P., **FLOREANI A.**, CARLOTTO A., BALDO V., BOZZOLA L., GIORDANI M.T., NEGRO F., RASSU M., TRAMARIN A., de LALLA F. Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg-Interferon alpha-2b plus ribavarin. *Aliment Pharmacol Ther* 21: 1173-1178, 2005 **IF 4.548**
- AA 91. **FLOREANI A.**, ROSA RIZZOTTO E., FERRARA F., CARDERI I., CAROLI D., BLASONE L., BALDO V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. *Am J Gastroenterol* 100: 1516-1522, 2005. **IF 7.553**
- AA 92. **FLOREANI A.**, NAVAGLIA F., BASSO D., ZAMBON C.F., BASSO G., GERMANO G., RIZZOTTO E.R., GUIDO M., PLEBANI M. Intron 2[IVS2, T-C+4] HFE gene mutation associated with S65C causes alternative RNA splicing and is responsible for iron overload. *Hepatol Res* 33: 57-60, 2005. **IF 2.072**

- AA 93. **FLOREANI A.**, MEGA A., CAMOZZI V., BALDO V., PLEBANI M., BURRA P., LUISETTO G. Is osteoporosis a peculiar association with primary biliary cirrhosis? *World J Gastroenterol* 11: 5347-5350, 2005. **IF 2.547**
- AA 94. RUCCI P., TALIANI G., CIRRINCIONE L., ALBERTI A., BARTOLOZZI D., CAPORASO N., COLOMBO M., COPPOLA R., CHIARAMONTE M., CRAXI' A., DE SIO I., **FLOREANI A.**, GAETA G.B., PERSICO M., SECCHI G., VERSACE I., MELE A. Validity and reability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life. *Dig Liver Dis* 37: 850-860, 2005. **IF 3.162**
- AA 95. **FLOREANI A.**, MINOLA E., CARDERI I., FERRARA F., RIZZOTTO E.R., BALDO V. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? *J Am Geriatr Soc* 54: 549-550, 2006. **IF 3.978**
- AA 96. **FLOREANI A.**, BONINSEGNA S., LOBELLO S., CAROLI D., FAGIUOLI S. Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal. *Gastroenterol Clin Biol* 30: 307-309, 2006. **IF 1.140**
- AA 97. **FLOREANI A.**, OSTUNI P.A., FERRARA F., GUIDO M. Primary biliary cirrhosis: When and why does the disease develop? *Dig Liver Dis* 38: 272-275, 2006. **IF 3.162**
- AA 98. **FLOREANI A.**, BETTERLE C., CARDERI I., PRESOTTO F., PEDINI B., MOSCON A., ANDREA O., CHIARAMONTE M., Arsita-one Research group. Is hepatitis C virus a risk factor for thyroid autoimmunity? *J Viral Hepat* 13: 272-277, 2006. **IF 3.082**
- AA 99. FABRIS P., TOSITTI G., GIORDANI M.T., BALDO V., GRASSO A., PIGNATTARI E., CANTON S., ROSSATO S., **FLOREANI A.** Assessing patients' understanding of hepatitis C virus infection and its impact on their lifestyle. *Aliment Pharmacol Ther* 23: 1161-1170, 2006. **IF 4.548**
- AA 100. **FLOREANI A.**, CARDERI I., VARIOLA A., ROSA RIZZOTTO E., NICOL J., BERGASA N.V. A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. *Hepatology* 43: 1152-1154, 2006. **IF 12.003**
- AA 101. **FLOREANI A.**, CARDERI I., PATERNOSTER D., SOARDO G., AZZAROLI F., ESPOSITO W., VARIOLA A., TOMMASI A.M., MARCHESONI D., BRAGHIN C., MAZZELLA G. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. *Aliment Pharmacol Ther* 23: 1649-1653, 2006. **IF 4.548**
- AA 102. MINOLA E., BALDO V., BALDOVIN T., TRIVELLO R., **FLOREANI A.** Intrafamilial transmission of hepatitis C virus infection. *Eur J Epidemiol* 21: 293-297, 2006. **IF 5.118**
- AA 103. TOMMASI A.M., FABRIS P, CARDERI I., BARAGIOTTA A., BALDO V., VENTURI C., GIORDANI M.T., TOSITTI G., **FLOREANI A.** Lack of higher frequency of the chemokine receptor 5-Delta32/Delta32 genotype in hepatitis C. *J Clin Gastroenterol* 40: 440-443, 2006. **IF 3.203**
- AA 104. BRUN P., CASTAGLIUOLO I., **FLOREANI A.**, BUDA A., BLASONE L., PALU' G., MARTINES D. Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. (letter). *Gut* 55: 1212, 2006. **IF 10.732**
- AA 105. DONALDSON P.T., BARAGIOTTA A., HENEGHAN M.A., **FLOREANI A.**, VENTURI C, UNDERHILL J.A., JONES D.E., JAMES O. F., BASSENDINE M.F. HLA class II alleles genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study. *Hepatology* 44: 667-674, 2006. **IF 12.003**
- AA 106 **FLOREANI A.**, NIRO G., ROSA RIZZOTTO E., ANTONIAZZI S., FERRARA F., CARDERI I., BALDO V., PREMOLI A., OLIVERO F., MORELLO E., DURAZZO M. Type 1 autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. *Aliment Pharmacol Ther* 24: 1151-1157, 2006. **IF 4.548**
- AA 107. GIANNINI E.G., ZAMAN A., KREIL A., **FLOREANI A.**, DULBECCO P., TESTA E., SOHAHEY R., VERHEY P., PECK-RADOSAVLJEVIC M., MANSI C., SAVARINO V., TESTA R. Platelet

count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. *Am J Gastroenterol* 101: 2511-1519, 2006. **IF 7.553**

- AA 108. BALDO V., BALDOVIN T., **FLOREANI A.**, MINUZZO M., TRIVELLO R. Response to influenza vaccine in people with non-protective HI antibody titers. *Eur J Epidemiol* 21: 843-845, 2006. **IF 5.118**
- AA 109. ONORI P., ALVARO D., **FLOREANI A.**, MANCINO M., FRANCHITTO A., GUIDO M., CARPINO G., DE SANTIS A., ANGELICO M., ATTILI A.F., GAUDIO E. Activation of IGF1 system characterizes cholangiocyte survival during the progression of primary biliary cirrhosis (PBC). *J Histochem Cytochem* 2006. **IF 2.255**
- AA 110. PELLI N., **FLOREANI A.**, TORRE F., DELFINO A., BARAGIOTTA A., CONTINI P., BASSO M., PICCIOTTO A., Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. *Clin Exp Immunol* 2007; 148: 85-89. **IF 3.409**
- AA 111. BALDO V., BALDOVIN T., **FLOREANI A.**, CARRARO A.M., TRIVELLO R. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. *Vaccine* 25: 3955-3961, 2007. **IF 3.492**
- AA 112. **FLOREANI A.**, CARDERI I., FERRARA F., ROSA RIZZOTTO E., LUISETTO G., CAMOZZI V., BALDO V. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis. *Digest Liver Dis* 39: 544-548, 2007. **IF 3.162**
- AA 113. **FLOREANI A.** Liver disease in the elderly: an update. *Dig Dis* 25: 138-143, 2007. **IF 2.725**
- AA 114. DONALDSON P., VEERAMANI S., BARAGIOTTA A., **FLOREANI A.**, VENTURI C., PEARCE S., WILSON V., JONES D., JAMES O., TAYLOR J., NEWTON J., BASSENDINE M. Cytotoxic T-lymphocyte-associated antigen-4 single nucleotide polymorphisms and haplotypes in primary biliary cirrhosis. *Clin Gastroenterol Hepatol* 5: 755-760, 2007. **IF 6.648**
- AA 115. BALDO V., BALDOVIN T., **FLOREANI A.**, FRAGAPANE E., TRIVELLO R., and The Family Medicine Group. Response to influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. *J Clin Immunol* 27: 542-547, 2007. **IF 3.382**
- AA 116. FEDERICO A., FILIPPELLI A., FALCIANI M., TUCCILLO C., TISO A., **FLOREANI A.**, NACCARATO R., ROSSI F., DEL VECCHIO BLANCO C., LOGUERCIO C. Platelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: in vivo and in vitro studies. *World J Gastroenterol* 13: 3677-3683, 2007 **IF 2.547**
- AA 117. **FLOREANI A.**, ROSA RIZZOTTO E., BASSO D., NAVAGLIA F., ZANINOTTO M., PETRIDIS I., DI ANDREA O., TESTA R., MARRA M., BALDO V., CHIARAMONTE M. An open population screening study for HFE gene major mutations proves the low prevalence of C282Y mutation in Central Italy. *Aliment Pharmacol Ther* 26: 577-586, 2007. **IF 4.548**
- AA 118. TALIANI G., RUCCI P., BILIOTTI E., CIRRINCIONE L., AGHEMO A., ALBERTI A., ALMASIO P.L., BARTOLOZZI D., CAPORASO N., COPPOLA R., CHIARAMONTE M., **FLOREANI A.**, GAETA G.B., PERSICO M., SECCHI G., VERSACE I., ZACHARIA S., MELE A. Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. *J Viral Hepat* 14: 875-882, 2007. **IF 3.082**
- AA 119. **FLOREANI A.**, CARDERI I., PATERNOSTER D., SOARDO G., AZZAROLI F., ESPOSITO W., MONTAGNANI M., MARCHESONI D., VARIOLA A., ROSA RIZZOTTO E., BRAGHIN C., MAZZELLA G. Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. *Dig Liver Dis*; 40: 366-370 2008 **IF 3.162**
- AA 120. PATERNOSTER D.M., BELLIGOLI A., NGARADOUMBE N.K., VISENTIN S., FRANCO R., FAGIUOLI S., BOLDRIN C., PALU' G., BALDO V., **FLOREANI A.** Endogenous interferon-alpha

level is increased in hepatitis C virus (HCV)-positive pregnant women. *J Clin Gastroenterol* 42: 204-207, 2008 **IF 3.203**

- AA 121. FABRIS P., BALDO V., BALDOVIN T., BELLOTTO E., RASSU M., TRIVELLO R., TRAMARIN A., TOSITTI G., **FLOREANI A.** Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. *J Clin Gastroenterol* 2008; 42: 527-532. **IF 3.203**
- AA 122. **FLOREANI A.**, BALDO V., RIZZOTTO E.R., CARDERI I., BALDOVIN T., MINOLA E. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis. *J Clin Gastroenterol* 42: 734-737, 2008 **IF 3.203**
- AA 123. BURRA P., MASIER A., MORISCO F., DI LEO V., ZORZI M., SENZOLO M., MARCHINI F., GUIDO M., CANOVA D., **FLOREANI A.**, BURROUGHS A.K. HCV infection in haemodialysed patients: a role for serum IL-10 and TGF-beta(1) in liver damage? *Dig Liver Dis* 2008 **IF 3.162**
- AA 124. **FLOREANI A.**, VARIOLA A., NIRO G., PREMOLI A., BALDO V., GAMBINO R., MUSSO G., CASSADER M., BO S., FERRARA F., CAROLI D., RIZZOTTO E.R., DURAZZO M. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. *Am J Gastroenterol* 103: 1-7, 2008 **IF 7.553**
- AA 125. BALDO V., BALDOVIN T., TRIVELLO R., **FLOREANI A.** Epidemiology of HCV infection. *Curr Pharmaceutical Des* 14: 1646-1654, 2008 **IF 3.311**
- AA 126. Wei L.X., **FLOREANI A.**, VARIOLA A., EL YOUNIS C, BERGASA N.V. A study of the Mu opioid receptor gene polymorphism A118G in patients with primary biliary cirrhosis with and without pruritus. *Acta Dermato-Veneorologica* 88: 323-326, 2008 **IF 3.487**
- AA 127. **FLOREANI A.** A novel approach for prevention and dissolution of cholesterol gallstones. *Liver Int* 28: 906-907, 2008. **IF 3.870**
- AA 128. MAJORI S., BALDO V., TOMMASI I., MALIZIA M., **FLOREANI A.**, MONTEIRO G., FERRARI A., ACCORDINI A., GUZZO P., BALDOVIN T. Hepatitis A, B and C infection in a community of Sub-Saharan immigrants living in Verona (Italy). *J Travel Med* 2008; 15: 323-327. **IF 1.683**
- AA 129. INVERNIZZI P., SELMI C., POLI F., FRISON S., **FLOREANI A.**, ALVARO D., ALMASIO P., ROSINA F., MARZIONI M., FABRIS L., MURATORI L., QI L., SELDIN M.F., GERSHWIN M.E., PODDA M.; Italian PBC Genetic Study Group. Human leucocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. *Hepatology* 2008; 48: 1906-1912. **IF 12.003**
- AA 130. DURAZZO M., NIRO G., PREMOLI A., MORELLO E., RIZZOTTO ER, GAMBINO R, BO S., MUSSO G., CASSADER M., PAGANO G., **FLOREANI A.** Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? *J Gastroenterol*; 44: 476-482, 2009 **IF 3.788**
- AA 131. CAVAZZA A., CABALLERIA L, **FLOREANI A.**, FARINATI F., BRUGUERA M., CAROLI D., PARES A. Incidence, risk factors and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. *Hepatology* 50: 1162-1168, 2009. **IF 12.003**
- AA 132. **FLOREANI A.**, LAZZARI R., PORZIONATO A., VARIOLA A., COLAVITO D., LEON A., GUIDO M., BALDO V., DE CARO R., BERGASA N.V. Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis. *J Gastroenterol* 45: 68-76, 2009 **IF 3.788**
- AA 133. **FLOREANI A.** Liver disorders in the elderly. *Best Pract Res Clin Gastroenterol* 2009; 23: 909-917. **IF 3.155**
- AA 134. **FLOREANI A.** Hepatitis C: Should antiviral therapy be offered to elderly patients? *Nat Rev Gastroenterol Hepatol* 6: 503-504, 2009 **IF 10.426**

- AA 135. BALDO V., BALDOVIN T., PELLEGRINI M., ANGIOLELLI G., MAJORI S., **FLOREANI A.**, BUSANA M.C., BERTONCELLO C., TRIVELLO R. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. *Clin Dev Immunol* 42: 517198, 2010. **IF 3.066**
- AA 136 LIU X., INVERNIZZI P., LU Y., KOSOY R., BIANCHI I., PODDA M., XU C., XIE G., MACCIARDI F., SELMI C., LUPOLI S., SHIGETA R., RANSOM M., LLEO A., LEE A.T., MASON A.L., MYERS R.P., PELTEKIAN K.M., GHENT C.N., BERNUZZI F., ZUIN M., ROSINA F., BORGHESIO E., **FLOREANI A.**, LAZZARI R., NIRO G., ANDRIULLI A., MURATORI L., MURATORI P., ALMASIO P.L., ANDREONE P., MARGOTTI M., BRUNETTO M., COCO B., ALVARO D., BRAGAZZI M.C., MARRA F., PISANO A., RIGAMONTI C., COLOMBO M., MARZIONI M., BENEDETTI A., FABRIS L., STRAZZABOISCO M., PORTINCASA P., PALMIERI V.O., TIRIBELLI C., CROCE' L., BRUNO S., ROSSI S., VINCI M., PRISCO C., MATTALIA A., TONIUTTO P., PICCIOTTO A., GALLI A., FERRARI C., COLOMBO S., CASELLA G., MORINI L., CAPORASO N., COLLI A., SPINZI G., MONTANARI R., GREGERSEN P.K., HEATHCOTE E.J., HIRSCHFELD G.M., SIMINOVITCH K.A., AMOS C.I., GERSHWIN M.E., SELDIN M.F. Genome-wide meta-analyses identify three loci Associated with primary biliary cirrhosis. *Nat Genet* 42: 658-660, 2010. **IF 35.209**
- AA 137 ALVARO D., CROCETTI E., FERRETTIS., BRAGAZZI MC., CAPOCACCIA R; AISF Cholangiocarcinoma Committee. Descriptive epidemiology of cholangiocarcinoma in Italy. *Dig Liver Dis* 42: 490-495, 2010 **IF 3.162**
- AA. 138 **FLOREANI A.**, NAVAGLIA F., ROSA RIZZOTTO E., BASSO D., CHIARAMONTE M., PADOAN A., PETRIDIS I., CAZZAGON N., TESTA R., MARRA M., PLEBANI M. Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload. *Clin Chem Lab Med* 49: 197-206, 2010 **IF 3.009**
- AA 139 **FLOREANI A.**, CAROLI D., VARIOLA A., ROSA RIZZOTTO E., ANTONIAZZI S., CHIARAMONTE M., CAZZAGON N., BROMBIN C., SALMASO L., BALDO V. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. *Liver Int* 31: 361-368, 2011 **IF 3.870**
- AA 140 **FLOREANI A.**, CAZZAGON N., FURLAN P., BALDOVIN T., EGOUE J., ANTONIAZZI S., BALDO V., MINOLA E. Retreatment of patients with chronic epatiti C relapsers to a previous antiviral treatment. *Eur J Gastroenterol Hepatol* 23: 511-515, 2011. **IF 1.915**
- AA 141 **FLOREANI A.**, CAZZAGON N., MARTINES D., CAVALLETTO L., BALDO V., CHEMELLO L. Performance and utility of transient elastography and non invasive markers of liver fibrosis in primary biliary cirrhosis. *Dig Liver Dis* 43; 887-892, 2011 **IF 3.162**
- AA 142 **FLOREANI A.**, PIZZUTI D., BERGASA NV., PETROSINO S. The endocannabinoid system in cholestasis. *Dig Liver Dis* 2011 **IF 3.162**
- AA 143 **FLOREANI A.**, CAZZAGON N., BOEMO DG., BALDOVIN T., BALDO V., EGOUE J., ANTONIAZZI S., MINOLA E. Female patients in fertile age with chronic hepatitis C, easy genotype and persistently normal transaminases have a 100% chance to reach a sustained virological response. *Eur J Gastroenterol Hepatol* 23: 977-1003, 2011 **IF 1.915**
- AA 144 **FLOREANI A.**, ANTONIAZZI S., MESCOLO C., BERGASA N.V. Hepatic methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C. *Eur J Gastroenterol Hepatol* 24: 427-430, 2012. **IF 1.915.**
- AA 145 LOGUERCIO C., ANDREONE P., BRISC C., BRISC M.C., BUGIANESI E., CHIARAMONTE M., CURSARO C., DANILA M., de SIO I., **FLOREANI A.**, FRENI M.A., GRIECO A., GROPPA M., LAZZARI R., LOBELLO S., LOREFICE E., MARGOTTI M., MIELE L., MILANI S., OKOLICSANYI L., PALASCIANO G., PORTINCASA P., SALTARELLI P., SMEDILE A., SOMALVICO F., SPADARO A., SPOREA I., SORRENTINO P., VECCHIONE R., TUCCILLO C., DEL VECCHIO BLANCO C., FEDERICO A. Sylbin combined with phosphatidylcholine and vitamin E in patients with non-alcoholic fatty liver disease: a randomized controlled trial. *Free Radic Biol Med* 52: 1658-1665, 2012. **IF 5.271**
- AA 146 BACQ Y., SENTILHES L., REYES H.B., GLANTZ A., KONDRACKIENE J., BINDER T., NICASTRI

P.L., LOCATELLI A., **FLOREANI A.**, HERNANDEZ I., DI MARTINO V. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. *Gastroenterology* 143: 1492-1501, 2012. **IF 12.821**

- AA 147 GRAMENZI A., CONTI F., CAMMA' C., GRIECO A., PICCIOTTO A., FURLAN C., ROMAGNO D., COSTA P., RENDINA M., ANCARANI F., CHIARAMONTE M., VERUCCHI G., CRAXI' A., BERNARDI M., ANDREONE P., AISF HepaElder Study Group. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. *Dig Liver Dis* 44: 674-680, 2012. **IF 3.162**
- AA 148 INVERNIZZI P., RANSOM M., RAYCHAUDHURI S., KOSOY R., LLEO A., SHIGETA R., FRANKE A., BOSSA F., AMOS C.I., GREGERSEN P.K., SIMINOVITCH K.A., CUSI D., de BAKKER P.I., PODDA M., GERSHWIN M.E., SELDIN M.F., ITALIAN PBC GENETICS STUDY GROUP. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. *Genes Immun* 13: 461-468, 2012. **IF 3.675**
- AA 149 JURAN B.D., HIRSCHFIELD G.M., INVERNIZZI P., ATKINSON E.J., LI Y., XIE G., KOSOY R., RANSOM M., SUN Y., BIANCHI I., SCHLICHT E.M., LLEO A., COLTESCU C., BERNUZZI F., PODDA M., LAMMERT C., SHIGETA R., CHAN L.L., BALSCHUN T., MARCONI M., CUSI D., HEATHCOTE E.J., MASON A.L., MYERS R.P., MILKIEWICZ P., ODIN J.A., LUKETIC V.A., BACON B.R., BODENHEIMER H.C., Jr, LIAKINA V., VINCENT C., LEVY C., FRANKE A., GREGERSEN P.K., BOSSA F., GERSHWIN M.E., deANDRATE M., AMOS C.I., ITALIAN PBC GENETICS STUDY GROUP, LAZARIDIS K.N., SELDIN M.F., SIMINOVITCH K.A. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. *Hum Mol Genet* 21: 5209-5221, 2012. **IF 7.692**
- AA 150 MONTAGNESE S., NSEMI L.M., CAZZAGON N., FACCHINI S., COSTA L., BERGASA N.V., AMODIO P., **FLOREANI A.** Sleep-wake profiles in patients with primary biliary cirrhosis. *Liver Int* 33: 203-209, 2013. **IF 3.870**
- AA 151 LLEO A., OERTELT-PRIGIONE S., BIANCHI I., CALIARI L., FINELLI P., MIOZZO M., LAZZARI R., **FLOREANI A.**, DONATO F., COLOMBO M., GERSHWIN M.E., PODDA M., INVERNIZZI P. Y chromosome loss in male patients with primary biliary cirrhosis. *J Autoimmun* 2013 **IF 8.145**
- AA 152 KAR S.P., SELDIN M.F., CHEN W., Lu E., HIRSCHFIELD G.M., INVERNIZZI P., HEATHCOTE J., CUSI D., THE ITALIAN PBC GENETICS STUDY GROUP, Almasio P.L., ALVARO D., ANDREONE P., ANDRIULLI A., BARLASSINA C., BENEDETTI A., BERNUZZI F., BIANCHI I., BRAGAZZI M., BRUNETTO M., BRUNO S., CALIARI L., CASELLA G., COCO B., COLLI A., COLOMBO M., COLOMBO S., CURSARO C., CROCE L.S., CROSIGNANI A., DONATO F., ELIA G., FABRIS L., **FLOREANI A.**, GALLI A., GRATTAGLIANO I., LAZZARI R., LLEO A., MACALUSO F., MARRA F., MARZIONI M., MASCIA E., MATTALIA A., MONTANARI R., MORINI L., MORISCO F., MURATORI L., MURATORI P., NIRO G., PICCIOTTO A., PODDA M., PORTINCASA P., PRATI D., RAGGI C., ROSINA F., ROSSI S., SOGNO I., SPINZI G., STRAZZABOSCO M., TARALLO S., TAROCCHI M., TIRIBELLI C., TONIUTTO P., VINCI M., ZUIN M., GERSHWIN M.E., SIMINOVITCH K.A., AMOS C.I. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. *Genes Immun* 2013, **IF 3.675**
- AA 153 **FLOREANI A.**, FARINATI F. Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis (letter). *Hepatology* 2013 **IF 12.003**
- AA 154 **FLOREANI A.**, CAROLI D., LAZZARI R., MEMMO A., VIDALI E., COLAVITO D., D'ARRIGO A., LEON A., ROMERO R., GERVASI M.T. Intrahepatic cholestasis of pregnancy: new insights into its pathogenesis. *J Matern Fetal Neonatal Med* 26: 1410-1415, 2013. **IF 1.518**
- AA 155 BAGGIO G., CORSINI A., **FLOREANI A.**, GIANNINI S., ZAGONEL V. Gender medicine: a task for the third millennium. *Clin Chem Lab Med* 51: 713-727, 2013. **IF 3.009**
- AA 156 LIU J.Z., HOV J.R., FOLSERAAS T., ELLINGHAUS E., RUSHBROOK S.M., DONCHEVA N.T., ANDREASSEN O.A., WEERSMA R.K., WEISMULLER T.J., EKSTEEN B., INVERNIZZI P., HIRSCHFIELD G.M., GOTTHARDT D.N., PARES A., ELLINGHAUS D., SHAH T., JURAN B.D., MILKIEWICZ P., RUST C., SCHRAMM C., MULLER T., SRIVASTAVA B., DALEKOS G., NOTHEN

M.M., HERMS S., WILKELMANN J., MITROVIC M., BRAUN F. PONSIOEN C.Y., CROUCHER P.J., STERNECK M., TEUFEL A., MASON A.L., SAARELA J., LEPPA V., DORFMAN R., ALVARO D., **FLOREANI A.**, ONENGUT-GUMUSCU S., RICH S.S., THOMPSON W.K., SCHORK A.J., NAESS S., THOMSEN I., MAYR G., KONIG I.R., HVEEM K., CLEYNEN I., GUTIERREZ-ACHURY J., RICANO-PONCE I., van HEEL D., BJORNSSON E., SANDFORD R.N., DIRIE P.R., MELUM E., VATN M.H., SILVERBERG M.S., DUERR R.H., PADYUKOV L., BRAND S., SANS M., ANNESE V., ACHKAR J.P., BOBERG K.M., MARSCHALL H.U., CHAZOUILLERES O., BOWLUS C.L., WIJMENGA C., SCHRUMPF E., VERMEIRE S., ALBRECHT M., UK-PSCSC Consortium, International IBD Genetics Consortium, RIOUX J.D., ALEXANDER G., BERGQUIST A., CHO J., SCHREIBER S., MANNS M.P., FARKKILA M., DALE A.M., CHAPMAN R.W., LAZARIDIS K.N., International PSC Study Group, FRANKE A., ANDERSON C.A., KARLSEN T.H. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nat Genet* 45: 670-675, 2013. **IF 35.209**

AA 157 FABRIS P., CARLOTTO A., BIANCO T.D., MALFATTI F., TRAMARIN A., MIOTTI M.A., BALDO V., **FLOREANI A.**, GIORDANI M.T., GRASSO A. Therapy of chronic hepatitis C with PEG-IFN a-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analysis. *Eur J Gastroenterol Hepatol* 2013. **IF 1.915**